Similar articles

• Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.

  Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Ozols RF, et al. Gynecol Oncol. 2006 Oct;103(1):1-6. doi: 10.1016/j.ygyno.2006.06.026. Epub 2006 Aug 10. Gynecol Oncol. 2006. PMID: 16904166 No abstract available.
• Intraperitoneal chemotherapy for ovarian cancer.

  Ozols RF, Bookman MA, Young RC. Ozols RF, et al. N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3. doi: 10.1056/NEJMc060264. N Engl J Med. 2006. PMID: 16611959 No abstract available.
• Intraperitoneal therapy for ovarian cancer: why has it not become standard?

  Rowan K. Rowan K. J Natl Cancer Inst. 2009 Jun 3;101(11):775-7. doi: 10.1093/jnci/djp151. Epub 2009 May 26. J Natl Cancer Inst. 2009. PMID: 19470952 No abstract available.
• [Prognostic factors of ovarian cancer].

  Ochiai K. Ochiai K. Gan To Kagaku Ryoho. 2006 Dec;33(13):2014-9. Gan To Kagaku Ryoho. 2006. PMID: 17197745 Review. Japanese.
• Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?

  Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM. Petignat P, et al. Crit Rev Oncol Hematol. 2007 May;62(2):137-47. doi: 10.1016/j.critrevonc.2006.11.009. Epub 2006 Dec 26. Crit Rev Oncol Hematol. 2007. PMID: 17188887 Review.